Here are relevant reports on : dna-sequencing-market
-
China Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Platforms, Bioinformatics), Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2031
The China Next-Generation Sequencing market, valued at USD 1.23 billion in 2025, stood at USD 1.35 billion in 2026 and is projected to advance at a resilient CAGR of 16.0% from 2026 to 2031, culminating in a forecasted valuation of USD 2.84 billion by the end of the period. Next-generation sequencing refers to advanced DNA and RNA sequencing technologies that enable rapid, high-throughput analysis of genetic material.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Europe Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture)-Forecast to 2030
The Europe Next-generation Sequencing Market, valued at US$4.11 billion in 2024, stood at US$4.42 billion in 2025 and is projected to advance at a resilient CAGR of 15.0% from 2025 to 2030, culminating in a forecasted valuation of US$8.88 billion by the end of the period. The Europe next-generation sequencing market is expanding on the back of accelerating use of sequencing across oncology, rare disease diagnostics, and broader precision medicine programs, supported by robust public and private research funding
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
South Korea Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing (Consumables), Platforms, Bioinformatics), Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2031
The South Korea next-generation sequencing market, valued at USD 0.19 billion in 2025, stood at USD 0.20 billion in 2026 and is projected to advance at a resilient CAGR of 14.0% from 2026 to 2031, culminating in a forecasted valuation of USD 0.39 billion by the end of the period. The report profiles key players such as Illumina Inc. (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), PacBio (US), and Oxford Nanopore Technologies plc. (UK).
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic, Industrial) - Global Forecast to 2028
The global metagenomic sequencing market, valued at US$1.8 billion in 2022, stood at US$2.0 billion in 2023 and is projected to advance at a resilient CAGR of 17.5% from 2023 to 2028, culminating in a forecasted valuation of US$4.5billion by the end of the period. NGS platforms have undergone continuous technological innovations over the last several years.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
North America Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture)-Forecast to 2030
The North America next-generation sequencing Market, valued at US$5.83 billion in 2024, stood at US$6.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.6% from 2025 to 2030, culminating in a forecasted valuation of US$11.63 billion by the end of the period. The expansion of the North American NGS market is driven by increasing adoption of sequencing in oncology and precision medicine, the growing prevalence of cancer and other chronic diseases, and ongoing advances that lower sequencing costs while enhancing throughput and data quality.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Global DNA and Gene Chip (Microarrays) Market (2010 – 2015)
The Global DNA & Gene Chip (microarray) market was valued at $760 million in 2010 and is expected to reach $1,425.2 million by 2015 growing at a CAGR of and 13.4%. The oDNA segment accounted for the largest share – 98% – of the global DNA & gene chip market in 2010.
- Published: May 2011
- Price: $ 4950
- TOC Available:
-
Biochips Market by Products & Services (Instruments, Software), Type (DNA Chips, Protein Chips, Lab-on-a-Chip), Application (High-throughput Screening, IVD, POC), Fabrication Technology (Microarrays, Microfluidics), & Region - Global Forecast to 2030
The global biochips market, valued at US$12,907.5 million in 2024, stood at US$14,011.6 million in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2024 to 2030, culminating in a forecasted valuation of US$21,356.4 million by the end of the period.
- Published: November 2025
- Price: $ 4950
- TOC Available:
-
Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031
The global epigenetics market is projected to reach USD 3.92 billion by 2031, growing at a CAGR of 12.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) - Global Forecast to 2026
The global aptamers market growth is primed to transition from $151 million in 2021 to $342 million by 2026, showcasing a strong CAGR of 17.7%. Growth of the market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
North America Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology]-Forecast to 2030
The North America epigenetics market, valued at USD 0.84 billion in 2024, stood at USD 0.93 billion in 2025 and is projected to advance at a resilient CAGR of 13.8% from 2025 to 2030, culminating in a forecasted valuation of USD 1.78 billion by the end of the period. Growth of the North America epigenetics market is driven by a strong, well-funded life sciences ecosystem, with rising oncology and precision-medicine programs that rely on methylation and chromatin profiling.
- Published: July 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
